We confirmed that CBP/P300 BRD inhibition can suppress tumor proliferation in several neutrophil-enriched TNBC models, and our findings suggested that high TAN frequency might predict a better response of TNBC to CBP/P300 BRD inhibitors. The gene discussed is EP300; the disease is neoplasm.